Merit Medical Systems, Inc. (MMSI) recently announced the U.S. commercial release of the basixSKY Inflation Device. The device is available as a standalone solution and in kits with Merit Medical’s Angioplasty Packs, configured to offer complementing AccessPLUS, Honor, and PhD hemostasis valves.The basixSKY is the latest addition to Merit Medical’s comprehensive inflation device portfolio, which includes both digital and analog devices.The inflation device portfolio belongs to Merit Medical’s Vascular – Car ...

Merit Medical Systems, Inc. (MMSI) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism led by solid first-quarter 2024 performance and its continued spend on research and development (R&D) are expected to contribute further. However, headwinds due to higher consolidation in the healthcare industry and forex volatility persist.Over the past year, this Zacks Rank #3 (Hold) stock has gained 1.4% compared with a 5.5% rise of the industry and 28.6% growth of t ...

SOUTH JORDAN, Utah, May 21, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced the US commercial release of the basixSKY Inflation Device. BasixSKY is the latest addition to Merit’s comprehensive inflation device portfolio, which includes both digital and analog devices. The basixSKY is available as a standalone solution and in kits with Merit Angioplasty Packs, configured to offer complementing AccessPLUS™, Honor®, and PhD™ hemosta ...

SOUTH JORDAN, Utah, May 21, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced the US commercial release of the basixSKY Inflation Device. BasixSKY is the latest addition to Merit’s comprehensive inflation device portfolio, which includes both digital and analog devices. The basixSKY is available as a standalone solution and in kits with Merit Angioplasty Packs, configured to offer complementing AccessPLUS™, Honor®, and PhD™ hemosta ...

SOUTH JORDAN, Utah, May 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced that its shareholders elected Silvia M. Perez, President of the Commercial Branding and Transportation Division at 3M Company, as a director in Merit's Annual Meeting of Shareholders held on May 15, 2024. Merit's shareholders also re-elected Fred P. Lampropoulos and Stephen C. Evans as directors. Ms. Perez and Messrs. Lampropoulos and Evans were elected t ...

SOUTH JORDAN, Utah, May 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced that its shareholders elected Silvia M. Perez, President of the Commercial Branding and Transportation Division at 3M Company, as a director in Merit's Annual Meeting of Shareholders held on May 15, 2024. Merit's shareholders also re-elected Fred P. Lampropoulos and Stephen C. Evans as directors. Ms. Perez and Messrs. Lampropoulos and Evans were elected t ...

Merit Medical Systems, Inc. (MMSI) recently received the FDA’s 510(k) clearance for its Siege Vascular Plug. The company also announced the launch of its Bearing nsPVA Express Prefilled Syringe in the United States and Australia.Merit Medical also announced its plans to introduce the Siege Vascular Plug and Bearing nsPVA Express at the upcoming Annual Global Embolization Oncology Symposium Technologies (GEST) Meeting. It will also exhibit other embolic product solutions, including Embosphere Microspheres, E ...

New products broaden Merit's leadership in embolotherapy.Full portfolio will be exhibited at the 18th Annual GEST Meeting May 16-19 in New York City. SOUTH JORDAN, Utah, May 14, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced US Food and Drug Administration (FDA) 510(k) clearance for its Siege Vascular Plug. Merit also announced the launch of its Bearing nsPVA Express Prefilled Syringe in the United States and Australia. The lates ...

Merit Medical Systems, Inc. (MMSI) delivered adjusted earnings per share (EPS) of 77 cents in the first quarter of 2024 compared with 64 cents in the year-ago period. The figure surpassed the Zacks Consensus Estimate by 8.5%.The adjustments include expenses related to the amortization of intangibles, and Medical Device Regulation expenses, among others.GAAP EPS for the quarter was 48 cents compared with 36 cents in the year-ago period.Revenues in DetailMerit Medical registered revenues of $323.5 million in ...

财务数据和关键指标变化 - 第一季度总收入为3.235亿美元,同比增长8.7%,按固定汇率计算同比增长9.3%,超出公司此前预期的6.5%-7.7%的增长范围 [17][18] - 非GAAP毛利润和营业利润分别同比增长10%和16%,毛利率和营业利润率分别同比提升约80个和115个基点 [19] - 非GAAP每股收益同比增长19%,超出公司预期 [19] 各条业务线数据和关键指标变化 - 心血管业务收入同比增长9%,内窥镜业务收入同比增长6% [33][34] - 外周介入产品收入增长19%,占心血管业务总增长的近80% [35] - 心脏介入和CPS产品收入均超出公司预期,分别增长7%和3% [38][39] - OEM产品收入同比中单位数下降,主要受客户库存优化影响 [40][41] 各个市场数据和关键指标变化 - 美国市场收入按固定汇率计算同比增长9%,有机同比增长5.5%,略低于公司预期 [43][44] - 国际市场收入按固定汇率计算同比增长9.5%,有机同比增长9%,超出公司预期 [46][47] - 中国市场收入同比增长22%,但公司预计2024年APAC地区收入将同比下降4% [47][48] 公司战略和发展方向及行业竞争 - 公司持续推出新产品,如1月获FDA批准的Scout MD手术导航系统,3月推出的Micro ACE微创介入系统等 [21][23] - 公司启动了MOTION膝关节骨性关节炎临床试验,并推进WAVE动静脉通路有效性临床试验 [26][29] - 公司有信心继续保持稳定的固定汇率收入增长、利润率改善和良好的自由现金流 [20] 管理层对经营环境和未来前景的评论 - 公司对2024年业务保持信心,预计第二季度收入同比增长4%-5%,非GAAP营业利润率为19.6%-19.9% [64][67] - 管理层表示不会在第一季度后调整全年指引,而是会在第二季度后再评估 [149][150] - 管理层对中国市场的长期前景保持信心,但短期内受到volume-based purchasing政策的不确定性影响 [172][173] 问答环节重要的提问和回答 问题1 **Craig Bijou 提问** 询问第二季度收入指引的假设和其他可能影响全年增长的因素 [91][92] **Raul Parra 回答** 解释第二季度收入指引的假设,包括收入增长、毛利率和每股收益的预期区间 [93][94][95][96][97] 问题2 **Jason Bednar 提问** 询问毛利率改善的可持续性以及来源 [108][109] **Raul Parra 回答** 解释毛利率改善的主要驱动因素,包括收入组合改善、定价提升、产品线转移等,并表示公司全年指引中预计毛利率和营业利润率将继续提升 [110][111][112][113] 问题3 **Jim Sidoti 提问** 询问中国市场收入下滑预期的原因及确定性 [163][164] **Joe Wright 和 Raul Parra 回答** 解释中国市场收入存在季度波动性,受volume-based purchasing政策影响,但公司已在指引中反映了这一不确定性 [165][166][167][168][169][170][171][172][173]